Effet de la tinzaparine sur la mortalité du cancer bronchique non à petites cellules opéré

G. Meyer; B. Besse; S. Friard; P. Girard; P. Corbi; R. Azarian; I. Monnet; M. Alifano; C. Chouaid; R. Descourt; G. Dennewald; L. Taillade; K. De Luca; F. Giraud; E. Pichon; G. Chatellier

doi:10.1016/j.rmr.2011.03.015

Effet de la tinzaparine sur la mortalité du cancer bronchique non à petites cellules opéré

G. Meyer, B. Besse, S. Friard, P. Girard, P. Corbi, R. Azarian, I. Monnet, M. Alifano, C. Chouaid, R. Descourt, G. Dennewald, L. Taillade, K. De Luca, F. Giraud, E. Pichon, G. Chatellier

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

12 Citations (Scopus)

Résumé

Experimental and clinical findings suggest that low molecular-weight heparins may improve overall survival in patients with cancer. The evidence is still limited and additional studies are needed to confirm these preliminary findings. Methods. Patients with completely resected stage I, II or IIIA (T3N1) histologically confirmed non-small-cell lung cancer will be included in a prospective, controlled, randomized, multicenter open trial. Patients in the control group will receive usual postoperative care including chemotherapy when indicated. Patients in the experimental group will receive tinzaparin given subcutaneously as a daily 100 IU/kg dose for 90 days along with usual postoperative care. Patients will be followed-up for three to eight years. Main end-point is the overall survival. Five hundred and fifty patients are needed to demonstrate a 10% absolute increase in survival in the experimental group. Expected results. A 10% absolute increase in the survival rate is expected in the patients receiving tinzaparin.

Titre traduit de la contribution	Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: Tinzaparin in lung tumours
langue originale	Français
Pages (de - à)	654-659
Nombre de pages	6
journal	Revue des Maladies Respiratoires
Volume	28
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/j.rmr.2011.03.015
état	Publié - 1 mai 2011

mots-clés

Adjuvant therapy
Heparin
Non-small-cell lung cancer
Survival
Tinzaparin

Accès au document

10.1016/j.rmr.2011.03.015

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Meyer, G., Besse, B., Friard, S., Girard, P., Corbi, P., Azarian, R., Monnet, I., Alifano, M., Chouaid, C., Descourt, R., Dennewald, G., Taillade, L., De Luca, K., Giraud, F., Pichon, E., & Chatellier, G. (2011). Effet de la tinzaparine sur la mortalité du cancer bronchique non à petites cellules opéré. Revue des Maladies Respiratoires, 28(5), 654-659. https://doi.org/10.1016/j.rmr.2011.03.015

@article{c1bd8edb1bb747bb8a8889c428cd66b1,

title = "Effet de la tinzaparine sur la mortalit{\'e} du cancer bronchique non {\`a} petites cellules op{\'e}r{\'e}",

abstract = "Experimental and clinical findings suggest that low molecular-weight heparins may improve overall survival in patients with cancer. The evidence is still limited and additional studies are needed to confirm these preliminary findings. Methods. Patients with completely resected stage I, II or IIIA (T3N1) histologically confirmed non-small-cell lung cancer will be included in a prospective, controlled, randomized, multicenter open trial. Patients in the control group will receive usual postoperative care including chemotherapy when indicated. Patients in the experimental group will receive tinzaparin given subcutaneously as a daily 100 IU/kg dose for 90 days along with usual postoperative care. Patients will be followed-up for three to eight years. Main end-point is the overall survival. Five hundred and fifty patients are needed to demonstrate a 10% absolute increase in survival in the experimental group. Expected results. A 10% absolute increase in the survival rate is expected in the patients receiving tinzaparin.",

keywords = "Adjuvant therapy, Heparin, Non-small-cell lung cancer, Survival, Tinzaparin",

author = "G. Meyer and B. Besse and S. Friard and P. Girard and P. Corbi and R. Azarian and I. Monnet and M. Alifano and C. Chouaid and R. Descourt and G. Dennewald and L. Taillade and {De Luca}, K. and F. Giraud and E. Pichon and G. Chatellier",

year = "2011",

month = may,

day = "1",

doi = "10.1016/j.rmr.2011.03.015",

language = "Fran{\c c}ais",

volume = "28",

pages = "654--659",

journal = "Revue des Maladies Respiratoires",

issn = "0761-8425",

number = "5",

}

Meyer, G, Besse, B, Friard, S, Girard, P, Corbi, P, Azarian, R, Monnet, I, Alifano, M, Chouaid, C, Descourt, R, Dennewald, G, Taillade, L, De Luca, K, Giraud, F, Pichon, E & Chatellier, G 2011, 'Effet de la tinzaparine sur la mortalité du cancer bronchique non à petites cellules opéré', Revue des Maladies Respiratoires, VOL. 28, Numéro 5, p. 654-659. https://doi.org/10.1016/j.rmr.2011.03.015

TY - JOUR

T1 - Effet de la tinzaparine sur la mortalité du cancer bronchique non à petites cellules opéré

AU - Meyer, G.

AU - Besse, B.

AU - Friard, S.

AU - Girard, P.

AU - Corbi, P.

AU - Azarian, R.

AU - Monnet, I.

AU - Alifano, M.

AU - Chouaid, C.

AU - Descourt, R.

AU - Dennewald, G.

AU - Taillade, L.

AU - De Luca, K.

AU - Giraud, F.

AU - Pichon, E.

AU - Chatellier, G.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Experimental and clinical findings suggest that low molecular-weight heparins may improve overall survival in patients with cancer. The evidence is still limited and additional studies are needed to confirm these preliminary findings. Methods. Patients with completely resected stage I, II or IIIA (T3N1) histologically confirmed non-small-cell lung cancer will be included in a prospective, controlled, randomized, multicenter open trial. Patients in the control group will receive usual postoperative care including chemotherapy when indicated. Patients in the experimental group will receive tinzaparin given subcutaneously as a daily 100 IU/kg dose for 90 days along with usual postoperative care. Patients will be followed-up for three to eight years. Main end-point is the overall survival. Five hundred and fifty patients are needed to demonstrate a 10% absolute increase in survival in the experimental group. Expected results. A 10% absolute increase in the survival rate is expected in the patients receiving tinzaparin.

AB - Experimental and clinical findings suggest that low molecular-weight heparins may improve overall survival in patients with cancer. The evidence is still limited and additional studies are needed to confirm these preliminary findings. Methods. Patients with completely resected stage I, II or IIIA (T3N1) histologically confirmed non-small-cell lung cancer will be included in a prospective, controlled, randomized, multicenter open trial. Patients in the control group will receive usual postoperative care including chemotherapy when indicated. Patients in the experimental group will receive tinzaparin given subcutaneously as a daily 100 IU/kg dose for 90 days along with usual postoperative care. Patients will be followed-up for three to eight years. Main end-point is the overall survival. Five hundred and fifty patients are needed to demonstrate a 10% absolute increase in survival in the experimental group. Expected results. A 10% absolute increase in the survival rate is expected in the patients receiving tinzaparin.

KW - Adjuvant therapy

KW - Heparin

KW - Non-small-cell lung cancer

KW - Survival

KW - Tinzaparin

UR - http://www.scopus.com/inward/record.url?scp=79959629149&partnerID=8YFLogxK

U2 - 10.1016/j.rmr.2011.03.015

DO - 10.1016/j.rmr.2011.03.015

M3 - Article

C2 - 21645836

AN - SCOPUS:79959629149

SN - 0761-8425

VL - 28

SP - 654

EP - 659

JO - Revue des Maladies Respiratoires

JF - Revue des Maladies Respiratoires

IS - 5

ER -